Lixisenatide
Lixisenatide
Lixisenatide (pronounced lix-i-sen-a-tide) is a type of glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) used in the treatment of Type 2 diabetes. It is marketed under the brand name Lyxumia in Europe and Adlyxin in the United States.
Etymology
The name "Lixisenatide" is derived from its chemical structure, which is a derivative of the naturally occurring hormone exendin-4. The "-atide" suffix is common in drugs that are peptides or mimic the action of peptide hormones.
Usage
Lixisenatide is used in combination with diet and exercise to improve blood sugar control in adults with type 2 diabetes. It is often used when diet and exercise alone does not control blood sugar. Lixisenatide is not used for the treatment of Type 1 diabetes or diabetic ketoacidosis.
Mechanism of Action
Lixisenatide works by increasing the release of insulin from the pancreas, reducing the amount of glucose produced by the liver, and slowing gastric emptying. This helps to control blood sugar levels and prevent long-term complications of diabetes.
Related Terms
- Glucagon-like peptide-1 receptor agonist
- Exendin-4
- Type 2 diabetes
- Type 1 diabetes
- Diabetic ketoacidosis
- Insulin
- Glucose
- Pancreas
- Liver
- Gastric emptying
External links
- Medical encyclopedia article on Lixisenatide
- Wikipedia's article - Lixisenatide
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski